Abstract
Inflammation is a complex response to local injury or other trauma which is characterized by redness, heat, swelling, and pain. Inflammation involves various immune system cells and numerous mediators. Inflammatory process is the net result of a cascade of highly regulated events propagated upon stimulation and is the major process through which the body repairs tissue damage and defends itself against foreign materials. Acute inflammation is typically caused by an external chemical, mechanical, or pathogenic influence; has a relatively short duration; and is a necessary protection tool that removes foreign bodies and damaged tissue, preventing further damage. Aberrant or chronic inflammation requires no external stimulus and can cause a range of painful and debilitating symptoms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Stevenson R, Hueber AJ, Hutton A, Graham D. Nanoparticles and inflammation. Sci. World J. 2011;11:1300–12.
Issa B, Obiat IM, Albiss BA, Haik Y. Magnetic nanoparticle. Int. J. Mol. Sci. 2013;14:21266–305.
Friedman AD, Claypool SE. Smart targeting of nanoparticles. Curr. Pharm. Des. 2013;19(35):6315–29.
Metselaar JM, Wauben MHM, Wagenaar-Hilbers JPA, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long circulating liposomes. Arthritis Rheum. 2003;48:2059–66.
Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen induced arthritis. Rheumatology. 1999;38:818–25.
Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta. 1995;1237:99–108.
Singh R, Lillard Jr JW. Nanoparticles based drug delivery. Exp. Mol. Pathol. 2009;86(3):215–23.
Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001;53:283–318.
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug. Del. Rev. 2003;55:329–47.
Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Control. Release. 2001;70:353–63.
Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 2001;299:775–81.
Fornaguera C, Dols-Perez A, Caldero G, García-Celma M, Camarasa J, Solans C. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier. J. Control. Release. 2015;211:134–43.
Treuel L, Jiang X, Nienhaus GU. New views on cellular uptake. J. Roy. Soc. Interface 2014;10:20120939.
Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy. 2005;4(3):281–6.
Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311–30.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Ray Banerjee, E. (2016). Nanomedicine: Nanoparticles and Its Relevance in Drug Discovery vis-a-vis Biomedicine. In: Perspectives in Translational Research in Life Sciences and Biomedicine. Springer, Singapore. https://doi.org/10.1007/978-981-10-0989-1_16
Download citation
DOI: https://doi.org/10.1007/978-981-10-0989-1_16
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-0988-4
Online ISBN: 978-981-10-0989-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)